Back

Restoration of E-cadherin Expression Alters Metastatic Organotropism in Invasive Lobular Breast Carcinoma Models

Savariau, L.; Tasdemir, N.; Thale, I. L.; Elangovan, A.; Ding, K.; John Mary, D. J. S.; Schlegel, B. T.; Xavier, J.; Hooda, J.; Lee, A. V.; Oesterreich, S.

2026-05-18 cancer biology
10.64898/2026.05.14.724680 bioRxiv
Show abstract

Invasive lobular carcinoma (ILC) is the most frequently diagnosed special histological subtype of invasive breast cancer and accounts for 10 - 15% of all cases. The pathognomonic hallmark of ILC is the genetic loss of E-cadherin (CDH1) causing the disruption of adherens junctions and resulting in discohesive, linear growth. To better understand the role of E-cadherin in ILC metastasis, we generated three ILC cell lines, MDA-MB-134-VI, SUM44PE, and BCK4, with inducible E-cadherin expression, resulting in successful restoration of functional adherens junctions. E-cadherin expression reduced growth in 2D culture, and that effect was even greater in 3D ultra-low attachment (ULA) conditions where increased cell death was consistent with the previously described role of E-cadherin in anoikis. E-cadherin expression did not rescue the lack of migration and invasion of ILC cell line models; however, it decreased haptotaxis and increased adherence to Collagen I in SUM44 cells. There was no significant effect of E-cadherin expression on primary orthotopic tumor growth, but spontaneous metastasis to the reproductive tract, brain, and GI tract was reduced. Inhibition of metastasis to the reproductive tract and brain was also seen after tail vein injection of MDA-MB-134 E-cadherin-expressing cells. In summary, overexpression of functional E-cadherin in ILC models has some, but limited, effects on 2D growth in vitro and primary tumor growth in vivo, but there are pronounced effects on 3D ULA growth and metastases in vivo, with stronger effects on metastatic sites enriched in patients with ILC, especially the reproductive and GI tracts.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
Cancers
200 papers in training set
Top 0.1%
27.5%
2
Breast Cancer Research
32 papers in training set
Top 0.1%
17.4%
3
International Journal of Cancer
42 papers in training set
Top 0.1%
8.4%
50% of probability mass above
4
PLOS ONE
4510 papers in training set
Top 28%
6.3%
5
Scientific Reports
3102 papers in training set
Top 19%
6.3%
6
Frontiers in Oncology
95 papers in training set
Top 2%
2.6%
7
Disease Models & Mechanisms
119 papers in training set
Top 0.8%
2.1%
8
Molecular Cancer Research
42 papers in training set
Top 0.3%
1.7%
9
BMC Cancer
52 papers in training set
Top 1%
1.7%
10
Molecular Oncology
50 papers in training set
Top 0.4%
1.7%
11
The Journal of Pathology
22 papers in training set
Top 0.2%
1.7%
12
npj Breast Cancer
18 papers in training set
Top 0.1%
1.5%
13
British Journal of Cancer
42 papers in training set
Top 1%
1.2%
14
eLife
5422 papers in training set
Top 49%
1.2%
15
Cancer Medicine
24 papers in training set
Top 1%
0.9%
16
Oncogene
76 papers in training set
Top 2%
0.9%
17
Cancer Research
116 papers in training set
Top 3%
0.9%
18
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 7%
0.9%
19
Cell Reports Medicine
140 papers in training set
Top 7%
0.8%
20
Cellular and Molecular Bioengineering
21 papers in training set
Top 0.4%
0.7%
21
Cell Communication and Signaling
35 papers in training set
Top 1%
0.6%
22
Annals of Oncology
13 papers in training set
Top 1%
0.6%